AUTHORS
Ding Quan Ng, PhD, Margaret Lam, MD2, Aniketh Tadepalli3, Satoko Ito, MD, PhD4, Jan Philipp Bewersdorf, MD5, George Goshua, MD, SM6
AFFILIATIONS
1 Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, United States
2 Brown University, Providence, United States
3 Yale School of Medicine, New Haven, Connecticut, United States
4 Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, United States
5 Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, United States
6 Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut, United States, Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, United States
ABSTRACT
*JPB and GG are co-senior authors
Introduction: Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by erythrocytosis with patients experiencing a heightened risk of arterial thrombotic events (ATEs) due to non-optimal hematocrit (Hct >45%) control with standard-of-care (SOC). Rusfertide, a first-in-class hepcidin mimetic, received FDA Breakthrough Therapy Designation due to efficacy in improving hematocrit control in randomized phase III VERIFY trial. This study determines the cost-effective price for rusfertide prior to FDA approval in the United States (US), incorporating benefits resulting from reducing phlebotomy rates to achieve hematocrit control with reduced symptom burden and decreased ATE risk.
Methods: We built a Markov cohort with a lifetime horizon from a US societal perspective. We sourced transition probabilities for hematocrit control and phlebotomy rates from phase III VERIFY trial data, with patients entering the model at age 57 to start on rusfertide or placebo. Reflecting VERIFY, discontinuation occurred either due to a lack of hematocrit control at six months or incident ATE, after which patients transitioned to real-world second-line cytoreduction. Background ATE risk was informed from the largest prospective PV natural history cohort, with ATE risk reduction due to appropriate hematocrit control (i.e., Hct <45%) based on the phase III CYTO-PV trial. PV-specific mortality rates were informed from population-based prospective cohorts, with background mortality informed from US life tables. Costs were assessed in 2025 US dollars and informed from the single largest US health insurer, Centers for Medicare & Medicaid Services, and supplemented with PV-specific healthcare resource utilization data. In addition, for societal costs we also considered productivity losses as a loss of four work hours per phlebotomy session, as well as due to ATE sequelae, assuming that patients with persistent neurologic disabilities had a family member as a caregiver and that they lost wages during the remaining of their working-age years. Effectiveness was measured in quality-adjusted life years (QALYs), and was parameterized with adjusted age- and sex-specific US general population utilities overlayed with disease-specific disutility adjustment for uncontrolled hematocrit in the context of a myeloproliferative neoplasm sourced from the 2019 Global Burden of Disease (GBD) Study. The primary outcome was the cost-effective maximum price for rusfertide expressed relative to the cost of hydroxyurea and ropeginterferon alfa-2b, the current first-line cytoreductive therapies for PV, across all accepted willingness-to-pay (WTP) thresholds with the base-case reporting at the recommended WTP threshold of $120,000/QALY. The secondary outcome was the incremental cost-effectiveness ratio (ICER) at the ropeginterferon alfa-2b-equivalent pricing for rusfertide. We concluded with sensitivity analyses to evaluate the effect of parameter variation on our model results.
Results: First without accounting for rusfertide drug cost (pending FDA approval), treatment with rusfertide versus SOC accrued 10.82 and 10.27 QALYs at costs of $832,000 and $1.00 million, respectively. Second, at ropeginterferon alfa-2b-equivalent pricing, rusfertide would not be cost-effective versus SOC, accruing 0.55 additional QALYs at an incremental cost of $763,000 (ICER $1.4 million/QALY; 95% credible interval $0.9-$3.1 million). Deterministic sensitivity analysis revealed that no parameter variation altered this conclusion, with the ICER most sensitive to rusfertide price. The maximum annual cost-effective price for rusfertide would be $29,600, which is 25.2% of ropeginterferon alfa-2b's annual cost and 249-fold (24,912%) that of hydroxyurea.
Conclusion: At a WTP threshold of $120,000/QALY, rusfertide would be cost-effective at an annual cost of up to $29,600. This is achieved by increasing the proportion of patients with optimal erythrocytosis control and, in turn, decreasing the burden of both the risks and costs associated with health resource utilization for patients with PV. Future analyses incorporating phase III long-term outcomes will further refine this estimate.
DISCLOSURES
Ding Quan Ng, PhD: No relevant conflicts of interest to declare.